Journal article
Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban
Abstract
BACKGROUND: Andexanet alfa (andexanet) is approved for specific anticoagulation reversal in patients with life-threatening or uncontrolled bleeding during treatment with rivaroxaban or apixaban. There is limited experience with andexanet in patients with acute bleeding on edoxaban.
METHODS: Patients with acute major bleeding within 18 hours of edoxaban intake were prospectively enrolled. Patients received a bolus and 2-hour follow-on infusion …
Authors
Benz AP; Xu L; Eikelboom JW; Middeldorp S; Milling TJ; Crowther M; Yue P; Conley P; Lu G; Connolly SJ
Journal
Thrombosis and Haemostasis, Vol. 122, No. 06, pp. 998–1005
Publisher
Thieme
Publication Date
June 2022
DOI
10.1055/s-0041-1740180
ISSN
0340-6245